Top Stories
ENV-308 was designed to mimic the appetite-suppressing effect of a natural hormone released post-exercise, called Lac-Phe.
The virtual cell world model is the first AI system to integrate the entire molecular-to-cellular spectrum into one continuous simulation.
The deal for ALE1 includes $275 million upfront, as well as up to $215 million in development and regulatory milestones.
The GLP-1 receptor antagonist met its primary endpoint in the Phase III LUCIDITY study by demonstrating a 55% reduction in the composite rate of level 2 and level 3 hypoglycaemic events compared to placebo.
GSK is now responsible for advancing experimental treatment AID351 through clinical development.
Conference News
Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas aeruginosa-colonised non-cystic fibrosis bronchiectasis (NCFB) patients, building on the positive toplin...
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding profil...
The demise of a BristolZeneca merger has increased investor pressure on AstraZeneca to meet its lofty revenue expectations for 2030, with all eyes now on front-line lung cancer data in AVANZAR.
Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028Ulviprubart sh...
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, SpainPresentation will r...
